Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 145

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 145
---
ies to the Merger Agreement entered into the Second Amendment to the Merger Agreement (the “Second Amendment”) which
amended and modified the Merger Agreement to, among other things, (i) reduce the size of NewGenIvf’s board of directors following
the consummation of the Business Combination to five (5) directors, two (2) of whom would be executive directors designated by NewGenIvf
and three (3) of whom will be designated by NewGenIvf to serve as independent directors in accordance with Nasdaq requirements, (ii)
provide for the conversion of NewGenIvf shares issued by NewGenIvf following the original date of the Merger Agreement into Class A Ordinary
Shares in connection with the Acquisition Merger, and (iii) remove the condition that ASCA have in excess of $5,000,000 in net tangible
assets immediately after the consummation of the Business Combination.

On April 3, 2024, the Business
Combination was consummated with the Company as the surviving entity.

NewGenIvf’s Business

With a focus on providing
fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely: (i) in vitro fertilization
(“IVF”) treatment service, comprising traditional IVF and egg donation; and (ii) surrogacy and ancillary caring services.
Currently, we have three clinics: one clinic in Thailand, one clinic in Cambodia, and one clinic in Kyrgyzstan.

<div align='center'>81</div>

For the years ended
December 31, 2024 and 2023, NewGenIvf’s revenue was US$5,433,375 and US$5,136,153, and its net income/(loss) was US$(474,101) and
US$108,418, respectively.

Market Opportunity

According to CIC, NewGenIvf’s
core market for fertility services is substantial and growing rapidly, driven by, among other things, societal and cultural shifts, such
as people starting families later in life and other health-related challenges which could impact couples’ and individuals’
ability to have children. In addition, NewGenIvf believes that continued overall de-stigmatization of infertility will help drive better
access to, and stronger demand for, fertility treatment services, thereby further enabling the expansion of NewGenIvf’s addressable
market. According to CIC, the market size of